Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

doi:10.1182/blood-2010-09-307280

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Blood - 24 Feb 2011

Taskesen Erdogan, Bullinger Lars, Corbacioglu Andrea, Sanders Mathijs A, Erpelinck Claudia A J, Wouters Bas J, van der Poel-van de Luytgaarde Sonja C, Damm Frederik, Krauter Jürgen, Ganser Arnold, Schlenk Richard F, Löwenberg Bob, Delwel Ruud, Döhner Hartmut, Valk Peter J M, Döhner Konstanze

Abstract excerpt

We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA(dm)) versus single mutations (CEBPA(sm)) in 1182 cytogenetically normal acute myeloid leukemia (AML) patients (16-60 years of age). We identified 151 (12.8%) patients with CEBPA mutations (91 CEBPA(dm) and 60 CEBPA(sm)). The incidence of germline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Protein-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Classification

Share to Leukemia, Myeloid, Acute

Share to Molecular Diagnostic Techniques

Share to Nucleophosmin

Share to Sensitivity and Specificity

Share to Survival Analysis

Share to Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 21177436
DOI: 10.1182/blood-2010-09-307280

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.PMID 21177436Read ↗

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.Semantic proximity Read ↗

The role of different genetic subtypes of CEBPA mutated AML.Semantic proximity Read ↗

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.Semantic proximity Read ↗

Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future DirectionsSemantic proximity Read ↗

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis.Semantic proximity Read ↗

Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.Semantic proximity Read ↗

Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significanceSemantic proximity Read ↗

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.Semantic proximity Read ↗

CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.Semantic proximity Read ↗

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.Semantic proximity Read ↗

CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.Semantic proximity Read ↗

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.